The Role of Prostagl<strong>and</strong>ins: Known <strong>and</strong> Unknown DangersAs a consequence of deficiencies such as these,investigators have been challenged to improve the clinical efficacy<strong>and</strong> acceptability of PGF 2•treatment, either by altering theroute of administration to allow a reduction in dosage orby using prostagl<strong>and</strong>ins of greater efficacy (pp. 1059–60,our emphasis)<strong>and</strong> implied that the ‘in press’ PG studies of Arpad Csapowould provide a concise underst<strong>and</strong>ing of the importantmechanisms of chemically induced abortion to avoid itsnegative elements (p. 1062).By 1972, the WHO Prostagl<strong>and</strong>in Task Force focused itschemical abortion program on the PGF 2•<strong>and</strong> PGE 2analogues,despite their abysmal abortion failure rates (WHO, 1972).Many of the factors 4 which determine the abortion successrate of PGs were identified subsequent to the program’scommencement, so that—like the current RU <strong>486</strong> promotion—it was a premature exercise. Here too, lies a further parallel,the general trend to acknowledge Bygdeman as the theoristresponsible for the PG abortion approach, just as there is toacknowledge Baulieu with the anti-progesterone approach,when in truth it was the theories of Csapo et al., which gavethe impetus to both PG <strong>and</strong> RU <strong>486</strong>-induced abortion. Wecondemn the practice of PG-induced terminations <strong>and</strong> opposePG usage with, or without, RU <strong>486</strong>.Based on the following statement we would have thoughtthat the WHO Scientific Group on Advances in Methods ofFertility Regulation was aware of the advantage ofconventional abortion methods: ‘It is evident that suctioncurettage is the method of choice for termination of pregnancyin the first 12 weeks of gestation. The method is associatedwith a surprisingly low incidence of complications as indicatedby results from e.g. Eastern Europe’ (1972: 92). WHO’smotive for discarding the conventional approach to abortionwas unclear. Particularly when at least one further importantreservation had emerged from the PG approach: ‘pregnancy93
RU <strong>486</strong>termination by in tra-amniotic PG cases beyond the 22ndweek was probably not recommendable, as the foetus maysometimes survive the procedure’ (idem.).Irrespective of motive, WHO trials proceeded,unconcerned that physiological PG levels were dramaticallyincreased by an experimental 25 mg amount of exogenousPG, albeit administered via the intra-amniotic route. Normally,in women these levels are in the nanogram or even pikogramrange (a nanogram [abbreviated to ng] being 0.001 mcg, <strong>and</strong>a pikogram [abbreviated to pk] being 0.000001 mcg). This 25mg dose, is the equivalent of 25,000 mcg or 25,000,000 ng ofPG <strong>and</strong> requires a 2.5 million-fold dilution by body fluids orchemical decay before physiological levels are restored withinthe cervical region of women subjected to this amount of PG.The biological consequences of outrageously excessive PGconcentrations, which may be further amplified by the use ofstable, synthetic PG analogues, is unknown.More recent PG-induced abortion procedures employintra-amniotic, intramuscular or intra-vaginal delivery of thePG derivatives. The PGE 2analogues, Cervagem(gemeprost) <strong>and</strong> Nalador (sulprostone) are those mostfrequently prescribed, gemeprost being a 1 mg vaginalpessary <strong>and</strong> sulprostone a 0.25 or 0.5 mg intramuscularinjection. A 1982 symposium on Cervagem ‘A NewProstagl<strong>and</strong>in in Obstetrics <strong>and</strong> Gynaecology’, valorizedSultan M.M. Karim as ‘the father, if not the gr<strong>and</strong>father, ofPGs in the field of obstetrics’. Karim (1983), in his report tothe symposium audience, listed the applications of exogenousPGs in gynecology <strong>and</strong> obstetrics that he judged to be themimicry of natural processes:94…menstrual induction/termination of very earlypregnancy, termination of first trimester pregnancy, preevacuationcervical dilation in first trimester of pregnancy,termination of abnormal intra-uterine pregnancy, preinductioncervical ripening, induction of labour, control
- Page 2 and 3:
Renate Klein is Lecturer in Women
- Page 4 and 5:
RU 486Misconceptions,Myths and Mora
- Page 6 and 7:
ACKNOWLEDGEMENTSWe would like to ex
- Page 8 and 9:
CONTENTSINTRODUCTION 1CHAPTER ONETh
- Page 10 and 11:
INTRODUCTIONInitial euphoria greete
- Page 12 and 13:
IntroductionUnfortunately, objectio
- Page 14 and 15:
Introductiondo not know or do not a
- Page 16 and 17:
Introductionused widely for years a
- Page 18 and 19:
CHAPTER ONEThe History of RU 486RU
- Page 20 and 21:
The History of RU 486consultants ar
- Page 22 and 23:
The History of RU 486Events in Fran
- Page 24 and 25:
The History of RU 486service of wom
- Page 26 and 27:
The History of RU 486The result app
- Page 28 and 29:
The History of RU 486developing cou
- Page 30 and 31:
The History of RU 486University Hos
- Page 32 and 33:
The History of RU 486pharmacovigila
- Page 34 and 35:
CHAPTER TWOClaims for RU 486/PG Abo
- Page 36 and 37:
Claims for RU 486/PG Abortionsevera
- Page 38 and 39:
Claims for RU 486/PG Abortionthe Br
- Page 40 and 41:
Claims for RU 486/PG Abortionan imm
- Page 42 and 43:
Claims for RU 486/PG Abortionby the
- Page 44 and 45:
Claims for RU 486/PG Abortionby the
- Page 46 and 47:
Claims for RU 486/PG Abortionfrom A
- Page 48 and 49:
Claims for RU 486/PG Abortioncommen
- Page 50 and 51:
Claims for RU 486/PG AbortionSome s
- Page 52 and 53: Claims for RU 486/PG Abortionbreeze
- Page 54 and 55: Claims for RU 486/PG Abortion18 per
- Page 56 and 57: Claims for RU 486/PG Abortion1. RU
- Page 58 and 59: Claims for RU 486/PG AbortionRU 486
- Page 60 and 61: Claims for RU 486/PG Abortionwider
- Page 62 and 63: Claims for RU 486/PG Abortionmedica
- Page 64 and 65: Claims for RU 486/PG Abortionreligi
- Page 66 and 67: What Is RU 486 and How Does It Work
- Page 68 and 69: What Is RU 486 and How Does It Work
- Page 70 and 71: What Is RU 486 and How Does It Work
- Page 72 and 73: What Is RU 486 and How Does It Work
- Page 74 and 75: What Is RU 486 and How Does It Work
- Page 76 and 77: What Is RU 486 and How Does It Work
- Page 78 and 79: What Is RU 486 and How Does It Work
- Page 80 and 81: What Is RU 486 and How Does It Work
- Page 82 and 83: What Is RU 486 and How Does It Work
- Page 84 and 85: What Is RU 486 and How Does It Work
- Page 86 and 87: What Is RU 486 and How Does It Work
- Page 88 and 89: What Is RU 486 and How Does It Work
- Page 90 and 91: The Role of Prostaglandins: Known a
- Page 92 and 93: The Role of Prostaglandins: Known a
- Page 94 and 95: The Role of Prostaglandins: Known a
- Page 96 and 97: The Role of Prostaglandins: Known a
- Page 98 and 99: The Role of Prostaglandins: Known a
- Page 100 and 101: The Role of Prostaglandins: Known a
- Page 104 and 105: The Role of Prostaglandins: Known a
- Page 106 and 107: The Role of Prostaglandins: Known a
- Page 108 and 109: The Role of Prostaglandins: Known a
- Page 110 and 111: The Role of Prostaglandins: Known a
- Page 112 and 113: The Role of Prostaglandins: Known a
- Page 114 and 115: The Role of Prostaglandins: Known a
- Page 116 and 117: The Role of Prostaglandins: Known a
- Page 118 and 119: The Role of Prostaglandins: Known a
- Page 120 and 121: The Role of Prostaglandins: Known a
- Page 122 and 123: ConclusionInstead, Baulieu uses the
- Page 124 and 125: Conclusionintervention. Thus, RU 48
- Page 126 and 127: Conclusionbetween population contro
- Page 128 and 129: ConclusionThis article, appearing i
- Page 130 and 131: Conclusion‘a whole net of relatio
- Page 132 and 133: ENDNOTESChapter One1The paten t lic
- Page 134 and 135: Endnotes12The Journal Officiel publ
- Page 136 and 137: Endnotesin Gynecology and Obstetric
- Page 138 and 139: Endnotesof menses. On the third day
- Page 140 and 141: EndnotesAnother such example is the
- Page 142 and 143: Bibliographyand Segal, Sheldon (Eds
- Page 144 and 145: Bibliographyprostaglandin F 2•. A
- Page 146 and 147: BibliographyDelaney, Anne. (1991, 2
- Page 148 and 149: Bibliographyresponses to the steroi
- Page 150 and 151: Bibliographyabnormalities resulting
- Page 152 and 153:
Bibliographyprogesterone receptor b
- Page 154 and 155:
BibliographyOdlind, Viveca and Birg
- Page 156 and 157:
BibliographyBinding of the anti-pro
- Page 158 and 159:
BibliographyUlmann, André, Teutsch
- Page 160:
Bibliographytermination by vacuum a